Sign in Subscribe
Pharmaceutical industry

Highly Effective and Safe Drug Regimen for Preventing HIV Transmission from Mother to Newborn

Strategic Insights

— 2 min read

Researchers from the Uganda-US study have found that a single oral dose of the antiretroviral drug nevirapine given to an HIV-infected woman in labor and another to her baby within three days of birth significantly reduces the transmission rate of HIV from mother to child. This regimen is more affordable and practical than any other examined to date, with the potential to prevent 300,000 to 400,000 newborns per year from being infected with HIV.

Key Takeaways:

  • The study, sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), found that a single oral dose of nevirapine given to an HIV-infected woman in labor and another to her baby within three days of birth reduces the transmission rate by half compared to a similar short-course of AZT.
  • The interim results from the study demonstrate that the nevirapine regimen resulted in a 47% reduction in mother-to-infant HIV transmission compared with a short-course of AZT.
  • The study investigators compared the safety and efficacy of two different short-course regimens of antiviral drugs administered late in pregnancy, with 618 mothers (308 receiving AZT and 310 receiving nevirapine) and their infants participating in the trial.
  • The nevirapine regimen was found to be safe and well-tolerated, with 13.1% of infants who received nevirapine being infected with HIV at 14-16 weeks of age, compared to 25.1% of those in the AZT group.
  • The study indicates that the cost of the nevirapine regimen is approximately 200 times cheaper than the long-course AZT used in the US, and almost 70 times cheaper than a short-course of AZT given to the mother during the last month of pregnancy.
  • Long-term follow-up of the mothers and their babies remains a high priority to assess any late drug toxicities as well as long-term survival.
  • Ugandan and US investigators will soon launch a follow-up study to evaluate the efficacy of nevirapine administered to the mother during labor and to the newborns for a longer period of time.

Statistics:

  • 618 mothers (308 receiving AZT and 310 receiving nevirapine) and their infants participated in the trial.
  • The nevirapine regimen resulted in a 47% reduction in mother-to-infant HIV transmission compared with a short-course of AZT.
  • 13.1% of infants who received nevirapine were infected with HIV at 14-16 weeks of age.
  • 25.1% of infants in the AZT group were infected with HIV at 14-16 weeks of age.
  • The cost of the nevirapine regimen is approximately 200 times cheaper than the long-course AZT used in the US.
  • The cost of the nevirapine regimen is almost 70 times cheaper than a short-course of AZT given to the mother during the last month of pregnancy.

Sources:

  • NIAID (National Institute of Allergy and Infectious Diseases)
  • Brooks Jackson, MD, Johns Hopkins University
  • Crispus Kiyonga, MBChB, Uganda's Minister of Health
  • UNAIDS (Joint United Nations Programme on HIV/AIDS)
  • CDC (Centers for Disease Control and Prevention)
  • Fred Hutchinson Cancer Research Center and the University of Washington School of Public Health and Community Medicine
  • Makerere University Faculty of Medicine
  • The Johns Hopkins University School of Medicine.

Read more